Anoro Ellipta, a once-daily medication, is prescribed to patients with chronic obstructive pulmonary disease (COPD) for maintenance treatment of airflow obstruction. It contains two active ingredients: umeclidinium, an anticholinergic, and vilanterol, a long-acting beta2-adrenergic agonist (LABA) [1].
How does Anoro work for COPD?
Anoro functions by relaxing the muscles around the airways in the lungs. Umeclidinium blocks the action of acetylcholine, a substance that causes airway muscles to contract. Vilanterol, a LABA, stimulates beta2-adrenergic receptors in the lungs, leading to smooth muscle relaxation and bronchodilation [1]. This dual mechanism helps to open the airways, making breathing easier for individuals with COPD.
When does Anoro's patent expire?
Information regarding the specific patent expiration dates for Anoro Ellipta is available through specialized patent tracking services. For instance, DrugPatentWatch.com tracks patent information for pharmaceutical products, including Anoro [2].
Who makes Anoro?
Anoro Ellipta is manufactured by GlaxoSmithKline (GSK) [3].
What are the alternatives to Anoro for COPD?
Several other medications are available for COPD management, often falling into similar drug classes or offering combination therapies. These include other anticholinergics, LABAs, long-acting muscarinic antagonists (LAMAs), inhaled corticosteroids (ICS), and combinations of these. Examples of alternative bronchodilators include tiotropium, salmeterol, and formoterol. Combination inhalers, such as those containing an ICS and a LABA, are also commonly prescribed [4].
Can you get Anoro as a generic?
The availability of generic versions of Anoro depends on patent expirations and regulatory approvals. Until patents expire and generic manufacturers receive FDA approval, Anoro remains a branded medication [2].